Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211445 · ClinicalTrials.gov registry record · Phase 2
Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)
A Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00211445 is a Phase 2 study that has completed, run by Manhattan Eye, Ear & Throat Hospital. The registered enrollment target is 11 participants.
The verdict
NCT00211445, a Phase 2 study, has completed, sponsored by Manhattan Eye, Ear & Throat Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Central serous choroidal (CSC) retinopathy is a disease of the macula characterized by exudation of fluid under the retina localized to the posterior pole as well as loss of vision. The etiology is unknown, but according to the studies this condition is more common in young males and is associated with type A personality. Clinically, CSC is characterized by serous retinal detachment and area of leakage of in the subretinal space. The standard of care for acute CSC is observation for a period of up to 3 months. If there is no complete resolution of the retinal detachment by 3 months, there is an indication for focal laser photocoagulation therapy of the area of leakage. This treatment is usually effective in stopping leakage of fluid under the retina and causing resolution of detachment. However, laser photocoagulation therapy is not beneficial in the treatment of chronic CSC because there is not a single easily identifiable point of leakage but rather diffuse disease of RPE thus rendering laser treatment ineffective.The purpose of this medical research study is to evaluate Verteporfin therapy as an approach which may benefit patients with CSC, based on observations in exudative type of AMD patients treated with Photodynamic Therapy using Verteporfin.
Interventions
- DRUG verteporfin
- PROCEDURE Photodynamic Therapy with Verteporfin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2002-07 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211445
The ClinicalTrials.gov registry entry for NCT00211445 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Manhattan Eye, Ear & Throat Hospital, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which verteporfin is the first listed.
NCT00211445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211445 about?
NCT00211445 is a clinical study titled "Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)". Central serous choroidal (CSC) retinopathy is a disease of the macula characterized by exudation of fluid under the retina localized to the posterior pole as well as loss of vision. The etiology is unknown, but according to the studies this condition is more common in young males and is associated w...
What is the current status of trial NCT00211445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2002-07. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00211445?
The interventions under investigation include: verteporfin (DRUG), Photodynamic Therapy with Verteporfin (PROCEDURE).
Who is sponsoring clinical trial NCT00211445?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.